359 related articles for article (PubMed ID: 31445190)
21. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
[TBL] [Abstract][Full Text] [Related]
22. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
23. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
24. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.
Garnelo M; Tan A; Her Z; Yeong J; Lim CJ; Chen J; Lim KH; Weber A; Chow P; Chung A; Ooi LL; Toh HC; Heikenwalder M; Ng IO; Nardin A; Chen Q; Abastado JP; Chew V
Gut; 2017 Feb; 66(2):342-351. PubMed ID: 26669617
[TBL] [Abstract][Full Text] [Related]
25. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
[TBL] [Abstract][Full Text] [Related]
26. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.
Wan YL; Zheng SS; Zhao ZC; Li MW; Jia CK; Zhang H
World J Gastroenterol; 2004 Jan; 10(2):195-9. PubMed ID: 14716821
[TBL] [Abstract][Full Text] [Related]
27. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.
Pedroza-Gonzalez A; Verhoef C; Ijzermans JN; Peppelenbosch MP; Kwekkeboom J; Verheij J; Janssen HL; Sprengers D
Hepatology; 2013 Jan; 57(1):183-94. PubMed ID: 22911397
[TBL] [Abstract][Full Text] [Related]
28. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
[TBL] [Abstract][Full Text] [Related]
29. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
30. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
[TBL] [Abstract][Full Text] [Related]
31. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
32. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137
Ugolini A; Zizzari IG; Ceccarelli F; Botticelli A; Colasanti T; Strigari L; Rughetti A; Rahimi H; Conti F; Valesini G; Marchetti P; Nuti M
EBioMedicine; 2020 Dec; 62():103098. PubMed ID: 33166793
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
34. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
35. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
36. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
37. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
38. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
Rohr-Udilova N; Klinglmüller F; Schulte-Hermann R; Stift J; Herac M; Salzmann M; Finotello F; Timelthaler G; Oberhuber G; Pinter M; Reiberger T; Jensen-Jarolim E; Eferl R; Trauner M
Sci Rep; 2018 Apr; 8(1):6220. PubMed ID: 29670256
[TBL] [Abstract][Full Text] [Related]
39. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
[TBL] [Abstract][Full Text] [Related]
40. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
